Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Despite COVID-19 Losses, IVD Executives Remain Upbeat

Companies report on Q1 2023 financials, looking for growth from expanded molecular testing menus

Continuing declines in COVID-19 test revenues was a common theme during the first quarter 2023 earning reports released by the nation’s largest in vitro diagnostics (IVD) manufacturers. At the same time, there was optimism as different IVD firms highlighted advancement and business opportunities in the following areas: • Digital pathology. • Companion diagnostics. • New …

Despite COVID-19 Losses, IVD Executives Remain Upbeat Read More »

To access this post, you must purchase The Dark Report.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.